Development asset linked to Seres Therapeutics in public FDA and regional records.
pharma · Clostridium Difficile Infection · Ulcerative Colitis · MCRB
Seres Therapeutics
Seres Therapeutics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Cambridge, USA HQ
2010 Founded
129 Employees
Public company Type
MCRB · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2010
- Employees
- 129
- Programs
- 8
- Drugs
- 7
- Patents
- 36
Seres Therapeutics pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Seres Therapeutics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to Seres Therapeutics in public FDA and regional records.
-
Development asset linked to Seres Therapeutics in public FDA and regional records.
-
Development asset linked to Seres Therapeutics in public FDA and regional records.
-
Development asset linked to Seres Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Peptidoglycan.
- Target
- Peptidoglycan
- Mechanism
- Peptidoglycan inhibitor